Kornitzer Capital Management Inc. KS acquired a new position in shares of West Pharmaceutical Services, Inc. (NYSE:WST - Free Report) in the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 21,000 shares of the medical instruments supplier's stock, valued at approximately $6,917,000.
A number of other hedge funds have also recently made changes to their positions in the stock. Pitcairn Co. lifted its holdings in West Pharmaceutical Services by 3.4% during the 1st quarter. Pitcairn Co. now owns 875 shares of the medical instruments supplier's stock worth $346,000 after buying an additional 29 shares in the last quarter. Copperwynd Financial LLC raised its stake in shares of West Pharmaceutical Services by 4.0% in the fourth quarter. Copperwynd Financial LLC now owns 778 shares of the medical instruments supplier's stock valued at $274,000 after acquiring an additional 30 shares in the last quarter. Clearbridge Investments LLC boosted its holdings in West Pharmaceutical Services by 0.7% in the first quarter. Clearbridge Investments LLC now owns 4,495 shares of the medical instruments supplier's stock valued at $1,779,000 after purchasing an additional 31 shares during the period. RFG Advisory LLC increased its holdings in West Pharmaceutical Services by 2.3% during the 1st quarter. RFG Advisory LLC now owns 1,465 shares of the medical instruments supplier's stock worth $580,000 after purchasing an additional 33 shares during the period. Finally, Peninsula Asset Management Inc. raised its position in West Pharmaceutical Services by 0.4% in the 4th quarter. Peninsula Asset Management Inc. now owns 9,580 shares of the medical instruments supplier's stock valued at $3,373,000 after purchasing an additional 35 shares in the last quarter. Hedge funds and other institutional investors own 93.90% of the company's stock.
Insider Transactions at West Pharmaceutical Services
In other news, VP Charles Witherspoon sold 1,029 shares of the company's stock in a transaction on Monday, August 19th. The shares were sold at an average price of $300.00, for a total value of $308,700.00. Following the completion of the transaction, the vice president now owns 1,478 shares in the company, valued at approximately $443,400. The sale was disclosed in a document filed with the SEC, which is available at this link. In other news, SVP Silji Abraham sold 1,800 shares of West Pharmaceutical Services stock in a transaction on Wednesday, June 12th. The shares were sold at an average price of $330.78, for a total value of $595,404.00. Following the transaction, the senior vice president now directly owns 2,860 shares of the company's stock, valued at approximately $946,030.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Charles Witherspoon sold 1,029 shares of the stock in a transaction on Monday, August 19th. The stock was sold at an average price of $300.00, for a total transaction of $308,700.00. Following the sale, the vice president now owns 1,478 shares of the company's stock, valued at approximately $443,400. The disclosure for this sale can be found here. Insiders own 0.53% of the company's stock.
West Pharmaceutical Services Stock Down 0.7 %
Shares of West Pharmaceutical Services stock traded down $2.07 on Friday, reaching $298.23. 173,386 shares of the company were exchanged, compared to its average volume of 553,509. The stock's 50 day moving average price is $308.00 and its 200-day moving average price is $341.75. The company has a market cap of $21.72 billion, a P/E ratio of 39.86, a price-to-earnings-growth ratio of 10.84 and a beta of 1.01. West Pharmaceutical Services, Inc. has a 1-year low of $265.00 and a 1-year high of $413.70. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.34 and a quick ratio of 1.68.
West Pharmaceutical Services (NYSE:WST - Get Free Report) last announced its quarterly earnings data on Thursday, July 25th. The medical instruments supplier reported $1.52 earnings per share for the quarter, missing analysts' consensus estimates of $1.74 by ($0.22). The firm had revenue of $702.10 million during the quarter, compared to analyst estimates of $729.36 million. West Pharmaceutical Services had a net margin of 18.25% and a return on equity of 19.17%. West Pharmaceutical Services's revenue for the quarter was down 6.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.11 earnings per share. As a group, equities analysts forecast that West Pharmaceutical Services, Inc. will post 6.44 EPS for the current year.
About West Pharmaceutical Services
(Free Report)
West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.
Featured Stories
- Five stocks we like better than West Pharmaceutical Services
- 3 Warren Buffett Stocks to Buy Now
- Does GTA VI Make Take-Two Interactive Stock an Irresistible Buy?
- How to Calculate Return on Investment (ROI)
- Why HPE’s Dip Is a Prime Opportunity for Blue-Chip AI Investors
- How to Plot Fibonacci Price Inflection Levels
- Why Analysts See Big Upside for Occidental Petroleum Despite Lows
→ Biden's Successor: The Radical Threat to YOUR Savings! (From Golden Crest) (Ad)
Should you invest $1,000 in West Pharmaceutical Services right now?
Before you consider West Pharmaceutical Services, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and West Pharmaceutical Services wasn't on the list.
While West Pharmaceutical Services currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Metaverse Stocks And Why You Can't Ignore Them
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
